These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 31485618)
21. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition. Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089 [TBL] [Abstract][Full Text] [Related]
22. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112 [TBL] [Abstract][Full Text] [Related]
23. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells. Wong SM; Liu FH; Lee YL; Huang HM PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740 [TBL] [Abstract][Full Text] [Related]
24. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells. Savickiene J; Treigyte G; Jonusiene V; Bruzaite R; Borutinskaite VV; Navakauskiene R Mol Cell Biochem; 2012 Jan; 359(1-2):245-61. PubMed ID: 21842375 [TBL] [Abstract][Full Text] [Related]
25. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro]. Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538 [TBL] [Abstract][Full Text] [Related]
26. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1. Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787 [TBL] [Abstract][Full Text] [Related]
27. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669 [TBL] [Abstract][Full Text] [Related]
28. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia. Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678 [TBL] [Abstract][Full Text] [Related]
29. Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells. Xie Q; Bai Q; Zou LY; Zhang QY; Zhou Y; Chang H; Yi L; Zhu JD; Mi MT Genes Chromosomes Cancer; 2014 May; 53(5):422-31. PubMed ID: 24532317 [TBL] [Abstract][Full Text] [Related]
30. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609 [TBL] [Abstract][Full Text] [Related]
31. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880 [TBL] [Abstract][Full Text] [Related]
34. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
35. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929 [TBL] [Abstract][Full Text] [Related]
36. Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid. Xiang L; Wang R; Wei J; Qiu G; Cen J; Hu S; Xie X; Chen Z; Gu W Acta Haematol; 2015; 133(3):279-86. PubMed ID: 25413479 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095 [TBL] [Abstract][Full Text] [Related]
38. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
39. miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. Pan B; Yang J; Wang X; Xu K; Ikezoe T Exp Hematol; 2018 Dec; 68():80-88.e2. PubMed ID: 30195077 [TBL] [Abstract][Full Text] [Related]
40. Effects of DNA Methylation on Leukemia Cell Proliferation. Kanda T; Nanmoku T; Oki K; Kawakami Y Clin Lab; 2020 Sep; 66(9):. PubMed ID: 32902233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]